HealthEquity (NASDAQ:HQY) Given New $120.00 Price Target at Raymond James

HealthEquity (NASDAQ:HQY) had its price target boosted by Raymond James from $105.00 to $120.00 in a research note published on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other equities analysts have also recently issued research reports about the company. Mizuho initiated coverage on HealthEquity in a report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price objective for the company. Royal Bank of Canada increased their price target on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. BTIG Research boosted their price target on HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Bank of America upped their price objective on HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Barrington Research raised their target price on shares of HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $113.54.

HealthEquity Stock Up 1.4 %

Shares of HealthEquity stock opened at $107.05 on Tuesday. HealthEquity has a 52-week low of $65.01 and a 52-week high of $115.59. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. The business’s 50 day simple moving average is $104.84 and its 200 day simple moving average is $93.08. The firm has a market cap of $9.28 billion, a PE ratio of 98.21, a P/E/G ratio of 1.60 and a beta of 0.55.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Monday, December 9th. The company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same quarter in the prior year, the business posted $0.40 earnings per share. On average, analysts predict that HealthEquity will post 2.32 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Stuart B. Parker sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $96.72, for a total transaction of $2,418,000.00. Following the transaction, the director now owns 19,061 shares in the company, valued at approximately $1,843,579.92. This trade represents a 56.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total value of $639,917.50. Following the sale, the director now directly owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,000 shares of company stock valued at $3,895,788 over the last ninety days. 2.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On HealthEquity

Hedge funds have recently bought and sold shares of the business. Wealthfront Advisers LLC bought a new stake in HealthEquity in the 4th quarter valued at about $10,304,089,000. Vanguard Group Inc. boosted its stake in shares of HealthEquity by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 8,976,091 shares of the company’s stock valued at $861,256,000 after buying an additional 99,624 shares during the period. Wasatch Advisors LP grew its position in HealthEquity by 6.6% during the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock worth $635,065,000 after buying an additional 483,269 shares in the last quarter. FMR LLC grew its position in HealthEquity by 2.4% during the fourth quarter. FMR LLC now owns 5,415,800 shares of the company’s stock worth $519,646,000 after buying an additional 125,684 shares in the last quarter. Finally, State Street Corp increased its stake in HealthEquity by 0.8% during the 3rd quarter. State Street Corp now owns 3,131,900 shares of the company’s stock worth $256,346,000 after acquiring an additional 23,613 shares during the period. 99.55% of the stock is owned by institutional investors.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.